AR114473A1 - Conjugados péptido-camptotecina - Google Patents
Conjugados péptido-camptotecinaInfo
- Publication number
- AR114473A1 AR114473A1 ARP190100908A ARP190100908A AR114473A1 AR 114473 A1 AR114473 A1 AR 114473A1 AR P190100908 A ARP190100908 A AR P190100908A AR P190100908 A ARP190100908 A AR P190100908A AR 114473 A1 AR114473 A1 AR 114473A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aminoalkyl
- cycloalkyl
- unit
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un Conjugado de Camptotecina de la fórmula (1): L-(Q-D)ₚ (1) o una sal farmacéuticamente aceptable de éste, donde L es una unidad de ligando; Q es una unidad ligante de la fórmula seleccionada entre: -Z-A-S*-RL-; -Z-A-LP(S*)-RL-; -Z-A-S*-RL-Y-; o -Z-A-LP(S*)-RL-Y-, donde Z es una unidad extendedora; A es un enlace o una unidad conectora; LP es una unidad conectora paralela; S* es un enlace o un agente de partición; RL es un péptido que comprende de 2 a 8 aminoácidos; e Y es una Unidad Espaciadora; D es una unidad de fármaco seleccionada entre: los compuestos de fórmulas (2) ó (3), donde RB es un miembro seleccionado del grupo que consiste en H, -alquil C₁₋₄-OH, -alquil C₁₋₄-O-alquil C₁₋₄-NH₂, -alquilo C₁₋₈, haloalquilo C₁₋₈, cicloalquilo C₃₋₈, cicloalquil C₃₋₈alquilo C₁₋₄, fenilo y fenilalquilo C₁₋₄; cada uno de RF y RF es un miembro seleccionado de modo independiente del grupo que consiste en H, alquilo C₁₋₈, hidroxialquilo C₁₋₈, aminoalquilo C₁₋₈, alquilo C₁₋₄aminoalquilo C₁₋₈, (hidroxialquilo C₁₋₄)(alquilo C₁₋₄)aminoalquilo C₁₋₈, di(alquilo C₁₋₄)aminoalquilo C₁₋₈, hidroxialquilo C₁₋₄aminoalquilo C₁₋₈, heteroalquilo C₂₋₆, alquilo C₁₋₈C(O)-, hidroxialquilo C₁₋₈C(O)-, aminoalquilo C₁₋₈C(O)-, cicloalquilo C₃₋₁₀, cicloalquilo C₃₋₁₀alquilo C₁₋₄, heterocicloalquilo C₃₋₁₀, heterocicloalquilo C₃₋₁₀alquilo C₁₋₄, fenilo, fenilalquilo C₁₋₄, difenilalquilo C₁₋₄, heteroarilo y heteroarilalquilo C₁₋₄; o RF y RF se combinan con el átomo de nitrógeno al cual cada uno de ellos está acoplado para formar un anillo de 5, 6 ó 7 miembros con 0 a 3 sustituyentes seleccionados entre halógeno, alquilo C₁₋₄, OH, O-alquilo C₁₋₄, NH₂, NH-alquilo C₁₋₄ y N(alquilo C₁₋₄)₂; y donde las porciones cicloalquilo, heterocicloalquilo, fenilo y heteroarilo de RB, RF y RF están sustituidas con 0 a 3 sustituyentes seleccionados entre halógeno, alquilo C₁₋₄, OH, O-alquilo C₁₋₄, NH₂, NH-alquilo C₁₋₄ y N(alquilo C₁₋₄)₂; y p representa de aproximadamente 1 a aproximadamente 16; donde Q está anexado a través de cualquiera de los grupos hidroxilo o amina presentes en CPT2 de fórmula (2) o CPT5 de fórmula (3).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862653961P | 2018-04-06 | 2018-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114473A1 true AR114473A1 (es) | 2020-09-09 |
Family
ID=68101237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100908A AR114473A1 (es) | 2018-04-06 | 2019-04-05 | Conjugados péptido-camptotecina |
Country Status (16)
Country | Link |
---|---|
US (2) | US20190343828A1 (es) |
EP (1) | EP3773736A4 (es) |
JP (2) | JP7430643B2 (es) |
KR (1) | KR20210006362A (es) |
CN (1) | CN111936169A (es) |
AR (1) | AR114473A1 (es) |
AU (1) | AU2019247434A1 (es) |
BR (1) | BR112020020466A2 (es) |
CA (1) | CA3094313A1 (es) |
EA (1) | EA202092410A1 (es) |
IL (2) | IL277748B1 (es) |
MA (1) | MA52669A (es) |
MX (1) | MX2020010458A (es) |
SG (1) | SG11202009527PA (es) |
TW (1) | TW202010498A (es) |
WO (1) | WO2019195665A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
CN110590796B (zh) * | 2018-06-12 | 2022-07-15 | 青岛海洋生物医药研究院股份有限公司 | 喜树碱衍生物及其制备方法和应用 |
WO2020219287A1 (en) | 2019-04-26 | 2020-10-29 | Immunogen, Inc. | Camptothecin derivatives |
BR112022004913A2 (pt) * | 2019-09-18 | 2022-06-07 | Baili Bio Chengdu Pharmaceutical Co Ltd | Derivado de camptotecina e conjugado do mesmo |
WO2021067820A1 (en) * | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
WO2021143741A1 (zh) * | 2020-01-15 | 2021-07-22 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
CN113274507A (zh) * | 2020-02-20 | 2021-08-20 | 亚飞(上海)生物医药科技有限公司 | 靶向递送和激活的免疫刺激性偶联复合物的制备和用途 |
WO2021173773A1 (en) * | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
CN116390770A (zh) | 2020-05-13 | 2023-07-04 | 思进股份有限公司 | 使用抗cd30抗体-药物缀合物的组合治疗癌症的方法 |
WO2022093794A1 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Methods of functionalizing nanoparticles |
KR20230133312A (ko) * | 2021-01-15 | 2023-09-19 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 캄프토테신 항체-약물 접합체 및 이의 사용 방법 |
US20240158410A1 (en) * | 2021-02-05 | 2024-05-16 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
US20240108745A1 (en) * | 2021-02-09 | 2024-04-04 | Medilink Therapeutics (Suzhou) Co., Ltd. | Bioactive substance conjugate, preparation method therefor and use thereof |
CN117015549A (zh) * | 2021-03-17 | 2023-11-07 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
TW202304929A (zh) * | 2021-04-29 | 2023-02-01 | 美商艾伯維有限公司 | 抗c-Met抗體藥物結合物 |
CN113527418B (zh) * | 2021-07-16 | 2022-05-03 | 成都普康唯新生物科技有限公司 | 一种ADC linker的制备方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
KR20240049583A (ko) * | 2021-08-19 | 2024-04-16 | 심시어 자이밍 파마슈티컬 컴퍼니 리미티드 | 캄프토테신 유도체, 이의 약학 조성물 및 이의 응용 |
AU2022350588A1 (en) | 2021-09-27 | 2024-05-02 | Evopoint Biosciences Co., Ltd. | Antibody, antibody-drug conjugate thereof and use thereof |
US20230158154A1 (en) * | 2021-11-09 | 2023-05-25 | Tubulis Gmbh | Conjugates comprising a phosphorus (v) and a camptothecin moiety |
WO2023143208A1 (zh) * | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023198884A1 (en) * | 2022-04-14 | 2023-10-19 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates with improved pharmacokinetic and drug release properties |
WO2023204631A1 (ko) * | 2022-04-20 | 2023-10-26 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
WO2023214849A1 (ko) * | 2022-05-04 | 2023-11-09 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체 |
CN117143178A (zh) * | 2022-05-30 | 2023-12-01 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法及其中间体 |
CN116789733A (zh) * | 2022-07-05 | 2023-09-22 | 上海药明合联生物技术有限公司 | 偶联连接子 |
WO2024013723A1 (en) * | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
KR20240035370A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체 |
WO2024078586A1 (en) | 2022-10-14 | 2024-04-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugate binding to human ptk7 and method for preparation and use thereof |
WO2024082051A1 (en) * | 2022-10-18 | 2024-04-25 | Zymeworks Bc Inc. | Antibody-drug conjugates targeting glypican-3 and methods of use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69209969T2 (de) | 1991-10-29 | 1996-09-12 | Glaxo Wellcome Inc | Wasserlösliche Camptothecinderivate |
JPH06228141A (ja) * | 1992-01-24 | 1994-08-16 | Takeda Chem Ind Ltd | 縮合複素環誘導体、その塩、その製造法および用途 |
US5496830A (en) * | 1994-09-14 | 1996-03-05 | Johns Hopkins University | Inhibition of hemoflagellates by camptothecin compounds |
TW464652B (en) * | 1996-10-30 | 2001-11-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
HUP0201480A3 (en) * | 1999-05-14 | 2009-03-30 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6629995B1 (en) * | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
US6825206B1 (en) * | 2000-11-16 | 2004-11-30 | Research Triangle Institute | Camptothecin compounds with a thioether group |
US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
CN101969970B (zh) * | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
IL301674A (en) | 2013-12-19 | 2023-05-01 | Seagen Inc | Methylene carbamate binders for use with drug-targeting conjugates |
JP7244987B2 (ja) * | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
TW202015740A (zh) * | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
-
2019
- 2019-04-05 IL IL277748A patent/IL277748B1/en unknown
- 2019-04-05 IL IL310391A patent/IL310391A/en unknown
- 2019-04-05 CN CN201980024331.XA patent/CN111936169A/zh active Pending
- 2019-04-05 JP JP2020554542A patent/JP7430643B2/ja active Active
- 2019-04-05 SG SG11202009527PA patent/SG11202009527PA/en unknown
- 2019-04-05 US US16/376,302 patent/US20190343828A1/en not_active Abandoned
- 2019-04-05 MX MX2020010458A patent/MX2020010458A/es unknown
- 2019-04-05 BR BR112020020466-8A patent/BR112020020466A2/pt unknown
- 2019-04-05 WO PCT/US2019/025968 patent/WO2019195665A1/en active Application Filing
- 2019-04-05 EP EP19781578.0A patent/EP3773736A4/en active Pending
- 2019-04-05 AU AU2019247434A patent/AU2019247434A1/en active Pending
- 2019-04-05 EA EA202092410A patent/EA202092410A1/ru unknown
- 2019-04-05 CA CA3094313A patent/CA3094313A1/en active Pending
- 2019-04-05 KR KR1020207031963A patent/KR20210006362A/ko unknown
- 2019-04-05 MA MA052669A patent/MA52669A/fr unknown
- 2019-04-05 AR ARP190100908A patent/AR114473A1/es unknown
- 2019-04-08 TW TW108112067A patent/TW202010498A/zh unknown
-
2021
- 2021-10-27 US US17/452,516 patent/US20220193069A1/en not_active Abandoned
-
2024
- 2024-01-31 JP JP2024012728A patent/JP2024042054A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020020466A2 (pt) | 2021-01-12 |
EP3773736A1 (en) | 2021-02-17 |
JP7430643B2 (ja) | 2024-02-13 |
TW202010498A (zh) | 2020-03-16 |
KR20210006362A (ko) | 2021-01-18 |
JP2021521111A (ja) | 2021-08-26 |
WO2019195665A1 (en) | 2019-10-10 |
US20220193069A1 (en) | 2022-06-23 |
CA3094313A1 (en) | 2019-10-10 |
JP2024042054A (ja) | 2024-03-27 |
EA202092410A1 (ru) | 2021-02-09 |
EP3773736A4 (en) | 2022-01-05 |
MX2020010458A (es) | 2021-01-29 |
IL277748B1 (en) | 2024-03-01 |
MA52669A (fr) | 2021-02-17 |
IL310391A (en) | 2024-03-01 |
AU2019247434A1 (en) | 2020-10-08 |
SG11202009527PA (en) | 2020-10-29 |
IL277748A (en) | 2020-11-30 |
CN111936169A (zh) | 2020-11-13 |
US20190343828A1 (en) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114473A1 (es) | Conjugados péptido-camptotecina | |
AR112689A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos | |
AR107154A1 (es) | Estimuladores de guanilato ciclasa soluble | |
AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
EA200970171A1 (ru) | Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
MD3313850T2 (ro) | Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin | |
AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
ECSP066671A (es) | Nuevos derivados de quinolina | |
AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
AR061643A1 (es) | Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1. | |
AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
AR068897A1 (es) | Inhibidores de proteasoma | |
AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR072798A1 (es) | Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa | |
AR092279A1 (es) | Pirrol carboxamidas fluorometilo sustituidas | |
PH12015502684A1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
AR121355A1 (es) | Compuestos antivirales | |
AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
HRP20080243T3 (en) | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |